A literature review of cyclodextrin inclusion complexes characterization - Part II: X-ray diffraction, infrared spectroscopy and nuclear magnetic resonance

International Journal of Pharmaceutical Sciences Review and Research

Volumn 12, Issue 1, 2012, Pages 8-15

  Takahashi, Andrea Ikeda ^a   Veiga, Francisco José Baptista ^b   Ferraz, Humberto Gomes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cyclodextrin; Infrared spectroscopy; Nuclear magnetic resonance; X ray diffraction

Indexed keywords

CYCLODEXTRIN;

ACCURACY; ANALYTIC METHOD; CHEMICAL BOND; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; ENCAPSULATION; INFRARED SPECTROSCOPY; INTERMETHOD COMPARISON; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PREDICTION; REVIEW; SENSITIVITY AND SPECIFICITY; X RAY DIFFRACTION;

EID: 84855516618     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Veiga FJB, Pecorelli CCMF, Ribeiro LSS, As ciclodextrinas em tecnologia farmacêutica. 1 ed., Minerva Coimbra Editora, Coimbra, 2006, 228p.
2. Corti G, Capasso G, Maestrelli F, Cirri M, Mura P, Physical-chemical characterization of binary systems of metformin hydrochloride with triacetyl-β-cyclodextrin, J. Pharm. Biomed. Anal., 45, 2007, 480-486.
3. Patel RP, Patel MM, Solid-state characterization and dissolution properties of lovastatin hydroxypropyl-β-cyclodextrin inclusion complex, Pharm. Tech., 31, 2007, 72-82.
4. Mura P, Bettinetti GP, Cirri M, Maestrelli F, Sorrenti M, Catenacci L, Solid-state characterization and dissolution properties of Naproxen-Arginine-Hydroxypropyl-β-cyclodextrin ternary system, Eur. J. Pharm. Biopharm., 59, 2005, 99-106.
5. Aleem O, Kuchekar B, Pore Y, Late S, Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrincomplexation on physicochemical properties and antimicrobial activity of cefdinir, J. Pharm. Biomed. Anal., 47, 2008, 535-540.
6. Ribeiro LSS, Ferreira DC, Veiga FJB,Physicochemical investigation of the effects of water-soluble polymers on vinpocetinecomplexation with β-cyclodextrin and its sulfobutyl ether derivate is solution and solid state, Eur. J. Pharm. Sci., 20, 2003, 253-266.
7. Zhang X, Zhang Y, Zhong D, Chen Y, Li S, Investigation and Physicochemical characterization of clarithromycin-citric acidcyclodextrins ternary complexes, Drug Dev. Ind. Pharm., 33, 2007, 163-171.
8. Toropainen T, Velaga S, Heikkilä T, Matilainen L, Jarho P, Carlfors J, Lehto VP, Järvinen T, Järvinem K, Preparation of budesonide/γ- cyclodextrin complexes in supercritical fluids with a novel SEDS method. emulsion based formulations, J. Pharm. Sci., 95, 2006, 2235-2245.
9. Vajna B, Farkas I, Farkas A, Pataki H, Nagy Z, Madarász J, Marosi G, Characterization of drug-cyclodextrin formulations using Raman mapping and multivariate curve resolution, J. Pharm. Biom. Anal., 56, 2011, 38-44.
10. Patil AL, Pore YV, Kuchekar BS, Late SG, Solid-state characterization and dissolution properties of bicalutamide-β-cyclodextrin inclusion complex, Pharmazie, 63, 2008, 282-285.
11. Scalia S, Coppi G, Iannuccelli V,Microencapsulation of a cyclodextrin complex of the UV filter, butyl methoxydibenzoylmethane: In vivo skin penetration studies, J. Pharm. Biom. Anal., 54, 2011, 345-350.
12. Jug M, Maestrelli F, Bragagni M, Mura P, Preparation and solidstate characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for bucal delivery, J. Pharm. Biom. Anal., 52, 2010, 9-18.
13. Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D, Trotta M, Zara G, Cavalli R,Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxity, Eur. J. Pharm. Biopharm., 74, 2010, 193-201.
14. AlOmari AA, AlOmari MM, Badwan AA, Al-Sou'Od KA, Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state, J. Pharm. Biom. Anal., 54, 2011, 503-509.
15. Hirlekar R, Kadam V,Preparation and characterization of inclusion complexes of carvedilol with methyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 63, 2009, 219-224.
16. Sinha VR, Anitha R, Ghosh S, AmitaKumria R, Bhinge JR, Kumar M, Physicochemical characterization and in vitrodissolution behaviour of celecoxib-β-cyclodextrin inclusion complexes, Acta Pharm., 57, 2007, 47-60.
17. Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP, Williams III RO, A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid, Eur. J. Pharm. Biopharm., 54, 2002, 271-280.
18. AlOmari MM, El-Barghouthi MI, Zughul MB, Davies JED, Dipyridamole/β-cyclodextrincomplexation: Effect of buffer species, thermodynamics, and guest-host interactions probed by 1H-NMR and molecular modeling studies, J. Incl. Phenom. Macrocycl. Chem., 64, 2009, 305-315.
19. Zoppi A, Garnero C, Linck YG, Chattah AK, Monti GA, Longhi MR, Enalapril:β-CD complex: Stability enhancement in solid state, Carbohydrate Polymers, 86, 2011, 716-721.
20. Cappello B, DiMaio C, Iervolino M, Miro A, Calignano A, Etodolac/cyclodextrin formulations: Physicochemical characterization and in vivo pharmacological studies, Drug Dev. Ind. Pharm., 35, 2009, 877-886.
21. Shah M, Karekar P, Sancheti P, Vyas V, Pore Y, Effect of PVP K30 and/or L-Arginine on stability constant of Etoricoxib-HPβCD inclusion complex: preparation and characterization of Etoricoxib- HPβCD binary system, Drug Dev. Ind. Pharm., 35, 2009, 118-129.
22. Al Omari MM, Badwan AA, Zughul MB, Davies JED, Fexofenadine/cyclodextrin inclusion complexation: phase solubility, thermodynamic, physicochemical and computational analisys, Drug Dev. Ind. Pharm., 33, 2007, 1205-1215.
23. Asbahr ACC, Franco L, Barison A, Silva CWP, Ferraz HG, Rodrigues LNC, Binary and ternary inclusion complexes of finasteride in HPβCD and polymers: Preparation and characterization, Bioorg. Med. Chem., 17, 2009, 2718-2723.
24. Wang S, Ding Y, Yao Y, Inclusion complexes of fluorofenidone with β -cyclodextrin and hydroxypropyl-β-cyclodextrin, Drug Dev. Ind. Pharm., 35, 2009, 808-813.
25. Ammar HO, Salama HA, Ghorab M, Mahmoud AA, Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems, Int. J. Pharm., 309, 2006, 129-138.
26. Cirri M, Righi MF, Maestrelli F, Mura P, Valleri M, Development of glyburide fast-dissolving tablets based on the combined use of cyclodextrins and polymers, Drug Dev. Ind. Pharm., 35, 2009, 73-82.
27. Cho HJ, Balakrishnan P, Shim WS, Chung SJ, Shim CK, Kim DD, Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethylcellulose for intranasal delivery, Int. J. Pharm., 400, 2010, 59-65.
28. Onyeji CO, Omoruyi SI, Oladimeji FA, Dissolution properties and characterization of halofantrine-2-hydroxypropyl-β-cyclodextrin binary systems, Pharmazie, 62, 2007, 858-863.
29. Hussei K, Türk M, Wahl MA, Comparative evaluation of ibuprofen/β-cyclodextrin complexes obtained by supercritical carbon dioxide and other conventional methods, Pharm. Res., 24, 2007, 585-592.
30. Mura P, Zerrouk N, Faucci MT, Maestrelli F, Chemtob C, Comparative study of ibuproxamcomplexation with amorphous β- cyclodextrin derivatives is solution and in solid state, Eur. J. Pharm. Biopharm., 54, 2002, 181-191.
31. Zhu XL, Wang HB, Chen Q, Yang WC, Yang GF, Preparation and characterization of inclusion complex of iprodione and β- cyclodextrin to improve fungicidal activity, J. Agric. Food Chem., 55, 2007, 3535-3539.
32. Hirlekar R, Kadam V, Preformulation Study of the Inclusion Complex Irbesartan-β-Cyclodextrin, AAPS Pharm. Sci. Tech., 10, 2009, 276-281.
33. Lee SY, Jung II, Kim JK, Lim GB, Ryu JH, Preparation of itraconazole/HP-β-CD inclusion complexes using supercritical aerosol solvent extraction system and their dissolution characteristics, J. Supercrit. Fluids., 44, 2008, 400-408.
34. Al-Marzouqi AH, Elwy HM, Shehadi I, Adem A, Physicochemical properties of antifungal drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques, J. Pharm. Biomed. Anal., 49, 2009, 227-233.
35. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P, Microspheres for colonic delivery of ketoprofen-hydroxypropyl-β-cyclodextrin complex, Eur. J. Pharm. Sci., 34, 2008, 1-11.
36. Shinde VR, Shelake MR, Shetty SS, Chavan-Patil AB, Pore YV, Late SG, Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique, J. Pharm. Pharmacol., 60, 2008, 1121-1129.
37. Obaidat AA, Khanfar RA, Khawam MN, The effect of β-cyclodextrin on the solubility and dissolution rate of meloxicam and investigation of the driving force for complexation using molecular modeling, J. Incl. Phenom. Macrocycl. Chem., 63, 2009, 273-279.
38. Wang J, Cai Z, Investigation of inclusion complex of miconazole nitrate with β- cyclodextrin, Carbohydr. Polym., 72, 2008, 255-260.
39. Figueiras A, Carvalho RA, Ribeiro L, Torres-Labandeira JJ, Veiga FJB, Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin, Eur. J. Pharm. Biopharm., 67, 2007, 531-539.
40. Yan Z, Xu W, Sun J, Liu X, Zhao Y, Sun Y, Zhang T, HE Z, Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-β-cyclodextrin, Drug Dev. Ind. Pharm., 34, 2008, 632-641.
41. Maestrelli F, Cecchi M, Cirri M, Capasso G, Mennini N, Mura P, Comparative study of oxaprozincomplexation with natural and chemically-modified cyclodextrins in solution and in the solid state, J. Incl. Phenom. Macrocycl., 63, 2009, 17-25.
42. Veiga MD, Merino M, Interactions of oxyphenbutazone with different cyclodextrins in aqueous medium and in the solid state, J. Pharm. Biomed. Anal., 28, 2002, 973-982.
43. Zhang X, Wu D, Lai J, Lu Y, Yin Z, Wu W, Piroxicam/2- Hydroxypropyl-β-Cyclodextrin Inclusion Complex Prepared by a New Fluid-Bed Coating Technique, J. Pharm. Sci., 98, 2009, 665-675.
44. Ghuzlaan A, AlOmari MM, Al-Sou'Od KA, Prednisone/cyclodextrin inclusion complexation: phase solubility, thermodynamic, physicochemical and computational analysis, J. Solution Chem., 38, 2009, 83-94.
45. Araújo MVG, Vieira EKB, Lázaro GS, Conegero LS, Ferreira OP, Almeida LE, Barreto LS, Costa-Jr NB, Gimenez IF,Inclusion complexes of pyrimethamine in 2-hydroxypropyl-β-cyclodextrin: Characterization, phase solubility and molecular modeling, Bioorg. Med. Chem., 15, 2007, 5752-5759.
46. Araujo DR, Tsuneda SS, Cereda CMS, Carvalho FDGF, Preté PSC, Fernandes SA, Yokaichiya F, Franco MKKD, Mazzaro I, Fraceto LF, Braga AFA, Paula E, Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-β-cyclodextrin inclusion complex, Eur. J. Pharm. Sci., 33, 2008, 60-71.
47. Sri KV, Kondaiah A, Ratna JV, Annapurna A, Preparation and characterization of quercetin and rutincyclodextrin inclusion complexes, Drug Dev. Ind. Pharm., 33, 2007, 245-253.
48. Rode T, Frauen M, Müler BW, Düsing HJ, Schonrock U, Mundt C, Wenck H, Complex formation of sericoside with hydrophilic cyclodextrins: improvement of solubility and skin penetration in topical emulsion based formulations, Eur. J. Pharm. Biopharm., 55, 2003, 191-198.
49. Rodriguez-Perez AI, Rodriguez-Tenreiro C, Alvarez-Lorenzo C, Taboada P, Concheiro A, Torres-Labandeira JJ, Sertaconazole / hydroxypropyl-β-cyclodextrincomplexation: isothermaltitrationcalorimetryandsolubility approaches, J. Pharm. Sci., 95, 2006, 1751-1762.
50. AlOmari MM, Zughul MB, Davies JED, Badwan AA, Sildenafil/cyclodextrincomplexation: Stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies, J. Pharm. Biomed. Anal., 41, 2006, 857-865.
51. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, Hwang SJ, Preparation and characterization of simvastatin/hydroxypropyl-β- cyclodextrin inclusion complex using supercritical antisolvent (SAS) process, Eur. J. Pharm. Biopharm., 66, 2007, 413-421.
52. Araújo MVG, Vieira EKB, Lázaro GS, Conegero LS, Ferreira OP, Almeida LE, Barreto LS, Costa-Jr NB, Gimenez IF,Sulfadiazine/hydroxypropyl-β-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling, Bioorg. Med. Chem., 16, 2008, 5788-5794.
53. Jug M, Kosalec I, Maestrelli F, Mura P, Analysis of triclosan inclusion complexes with β-cyclodextrin and its water-soluble polymeric derivative, J. Pharm. Biom. Anal., 54, 2011, 1030-1039.
54. Doiphode D, Gaikwad S, Pore Y, Kuchekar B, Late S, Effect of β- cyclodextrincomplexation on physicochemical properties of zaleplon, J. Incl. Phenom. Macrocycl. Chem., 62, 2008, 43-50.
55. Eid EEM, Abdul AB, Suliman FEO, Sukari MA, Rasedee A, Fatah SS, Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin, Carbohydrate Polymers, 83, 2011, 1707-1714.
56. Yang X, Ke W, Zi P, Liu F, Yu L, Detecting and identifying the complexation of nimodipine with hydroxypropyl-β-cyclodextrin present in tablets by Raman spectroscopy, J. Pharm. Sci., 97, 2008, 2702-2719.
57. Beijnen JH, Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L, Complexation study of the anticancer agent EO-9 with 2- hydroxypropyl-β-cyclodextrin, Drug Dev. Ind. Pharm., 34, 2008, 1130-1139.
58. Yuan C, Jin Z, Xu X, Zhuang H, Shen W, Preparation and stability of the inclusion complex of astaxanthin with hydroxypropyl-β-cyclodextrin, Food Chem., 109, 2008, 264-268.
59. Lee PS, Han JY, Song TW, Sung JH, Kwon OS, Song S, Chung YB, Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with β- cyclodextrin, Int. J. Pharm., 316, 2006, 29-36.
60. Nagarsenker MS, Joshi MS, Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage, Drug Dev. Ind. Pharm., 31, 2005, 169-178.
61. Dahiya S, Pathak K, Influence of amorphous cyclodextrin derivatives on aceclofenac release from directly compressible tablets, Pharmazie, 62, 2007, 278-283.
62. Granero GE, Maitre MM, Garnero C, Longhi MR, Synthesis, characterization and in vitro release studies of a new acetazolamide-HP-β-CD-TEA inclusion complex, Eur. J. Med. Chem., 43, 2008, 464-470.
63. Jug M, Becirevic-Lacan M, Bengez S, Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol, Drug Dev. Ind. Pharm., 35, 2009, 796-807.
64. Li N, Xu L, Thermal analysis of β-cyclodextrin/Berberine chloride inclusion compounds, ThermochimicaActa, 499, 2010, 166-170.
65. Castelli VVA, Trivieri G, Zucchelli I, Brambilla L, Barbuzzi T, Castiglioni C, Paci M, Zerbi G, Zanol M, Characterization of an inclusion complex between cladribine and 2-hydroxypropyl-β- cyclodextrin, J. Pharm. Sci., 97, 2008, 3897-3906.
66. Dias K, Nikolau S, De Giovani WF, Synthesis and spectral investigation of Al(III) catechin/β-cyclodextrin and Al(III) quercetin/β-cyclodextrin inclusion compounds,Spectrochim. Acta, Part A, 70, 2008, 154-161.
67. Kim JK, Kim MS, Park JS, Kim CK, Thermo-reversible flurbiprofen liquid suppository with HP-β-CD as a solubility enhancer: improvement of rectal bioavailability, J. Incl. Phenom. Macrocycl. Chem., 64, 2009, 265-272.
68. Cirri M, Bragagni M, Mennini N, Mura P, Development of a new delivery system consisting in "drug - in cyclodextrin - in nanostructured lipid carriers" for ketoprofen topical delivery, Eur. J. Pharm. Biopharm., 2011, doi: 10.1016/j.ejpb.2011.07.015.
69. Nacsa A, Ambrus R, Berkesi O, Szabó-Révéz P, Aigner Z, Watersoluble loratadine inclusion complex: Analytical control of the preparation by microwave irradiation, J. Pharm. Biomed. Anal., 48, 2008, 1020-1023.
70. Nacsa A, Berkesi O, Szabó-Révész P, Aigner Z, Achievement of pHindependence of poorly-soluble, ionizableloratadine by inclusion complex formation with dimethyl-b-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 64, 2009, 249-254.
71. Jug M, Becirevic-Lacan M, Development of a cyclodextrin-based nasal delivery system for lorazepam, Drug Dev. Ind. Pharm., 34, 2008, 817-826.
72. Banchero M, Manna L, Investigation of the piroxicam/hydroxypropyl-β-cyclodextrin inclusion complexation by means of a supercritical solvent in the presence of auxiliary agents, J.Supercrit.Fluid., 57, 2011, 259-266.
73. Song LX, Guo XQ, Du FY, Bai L, Thermal degradation comparison of polypropylene glycol and its complex with β-cyclodextrin, Polym.Degrad. Stabil., 95, 2010, 508-515.
74. Rajabi O, Tayyari F, Salari R, Tayyari SF, Study of interaction of spironolactone with hydroxypropyl-β-cyclodextrin in aqueous solution and in solid state, J. Mol. Struct., 878, 2008, 78-83.
75. Misiuk W, Zalewska M, Investigation of inclusion complex of trazodone hydrochloride with hydroxypropyl-β-cyclodextrin, Carbohydr. Polym., 77, 2009, 482-488.
76. Figueiras A, Sarraguça JMG, Carvalho RA, Pais AACC, Veiga FJB, Interaction of omeprazole with a methylated derivative of β- cyclodextrin: Phase solubility, NMR spectroscopy and molecular simulation, Pharm. Res., 24, 2007, 377-389.
77. Pinto LMA, Fraceto LF, Santana MHA, Pertinhez TA, Oyama-Jr S, De Paula E, Physico-chemical characterization of benzocaine-β- cyclodextrin inclusion complexes, J. Pharm. Biomed. Anal., 39, 2005, 956-963.
78. Borodi G, Bratu I, Dragan F, Peschar R, Helmholdt RB, Hernanz A, Spectroscopic investigations and crystal structure from synchrotron powder data of the inclusion complex of β- cyclodextrin with atenolol, Spectrochim. Acta, Part A, 70, 2008, 1041-1048.
79. Garnero C, Longhi M, Study of ascorbic acid interaction with hydroxypropyl-β-cyclodextrin and triethanolamine, separately and in combination, J. Pharm. Biomed. Anal., 45, 2007, 536-545.
80. Sagiraju S, Jursic B, NMR spectroscopic study of cyclodextrin inclusion complexes with A-007 prodrugs, Carbohydr. Res., 343, 2008, 1180-1190.
81. Yang ZX, Chen Y, Liu Y, Inclusion complexes of bisphenol A with cyclomaltoheptaose (β-cyclodextrin): solubilization and structure, Carbohydr. Res., 343, 2008, 2439-2442.
82. Capello B, DiMaio C, Iervolino M, Miro A, Combined effect of hydroxypropyl methylcellulose and hydroxypropyl-β-cyclodextrin on physicochemical and dissolution properties of celecoxib, J. Incl. Phenom. Macrocycl. Chem., 59, 2007, 237-244.
83. Misiuk W, Zalewska M, Study on the inclusion interactions of β- cyclodextrin and its derivatives with clomipramine by spectroscopy and its analytic application. Anal.Lett., 41, 2008, 543-560.
84. Franco C, Schwingel L, Lula I, Sinisterra RD, Koester LS, Bassani VL, Studies on coumestrol/β-cyclodextrin association: Inclusion complex characterization, Int. J. Pharm., 369, 2009, 5-11.
85. He J, Deng L, Yang S, Synthesis and characterization of β- cyclodextrin inclusion complex containing di(8- hydroxyquinoline)magnesium, Spectrochim. Acta, Part A, 70, 2008, 878-883.
86. Mehta SK, Bhasin KK, Dham S, Energetically favorable interactions between diclofenac sodium and cyclodextrin molecules in aqueous media, J. Colloid Interface Sci., 326, 2008, 374-381.
87. Cruz JR, Becker BA, Morris KF, Larive CK, NMR characterization of the host-guest inclusion complex between β-cyclodextrin and doxepin, Magn. Reson. Chem., 46, 2008, 838-845.
88. Zoppi A, Quevedo MA, Longhi MR, Specific binding capacity of β- cyclodextrin with cis and trans enalapril: Physicochemical characterization and structural studies by molecular modeling, Bioorg. Med. Chem., 116, 2008, 8403-8412.
89. Sousa FB, Denadai AML, Lula IS, Lopes JF, Dos Santos HF, De Almeida WB, Sinisterra RD, Supramolecular complex of fluoxetine with β-cyclodextrin: an experimental and theoretical study, Int. J. Pharm., 353, 2008, 160-169.
90. Grillo R, Melo NFS, Moraes CM, Lima R, Menezes CMS, Ferreira EI, Rosa AH, Fraceto LF, Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-β-cyclodextrin, J. Pharm. Biomed. Anal., 47, 2008, 295-302.
91. Di Cagno M, Stein PC, Skalko-Basnet N, Brandl M, Bauer-Brandl A, Solubilization of ibuprofen with β-cyclodextrin derivatives: Energetic and structural studies, J. Pharm. Biomed. Anal., 55, 2011, 446-451.
92. De Paula W, Denadai AML, Santoro MM, Braga ANG, Santos RAS, Sinisterra RD,Supramolecular interactions beween losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and antihypertensive studies, Int. J. Pharm., 404, 2011, 116-123.
93. Jullian C, Cifuentes C, Alfaro M, Miranda S, Barriga G, Olea-Azar C, Spectroscopic characterization of the inclusion complexes of luteolin with native and derivatized β-cyclodextrin, Bioorganic & Medicinal Chemistry, 18, 2010, 5025-5031.
94. Barillaro V, Dive G, Bertholet P, Evrard B, Delattre L, Frederich M, Ziémons E, Piel G, Theoretical and experimental investigations of organic acids/cyclodextrin complexes and their consequences upon the formation of miconazole/cyclodextrin/acid ternary inclusion complexes, Int. J. Pharm., 347, 2008, 62-70.
95. Ali SM, Upadhyay SK,Complexation study of midazolam hydrochloride with β-cyclodextrin: NMR spectroscopic study in solution, Magn. Reson. Chem., 46, 2008, 676-679.
96. Jullian C, Morales-Montecinos J, Zapata-Torres G, Aguilera B, Rodriguez J, Arán V, Olea-Azar C, Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins, Bioorg. Med. Chem., 16, 2008, 5078-5084.
97. Bernat V, Ringard-Lefebvre C, Le Bas G, Perly B, Djedaïni-Pilard F, Lesieur S, Inclusion complex of n-octyl β-D-glucopyranoside and α- cyclodextrin in aqueous solutions: thermodynamic and structural characterization, Langmuir, 24, 2008, 3140-3149.
98. Li J, Zhao C, Chao J, Investigation on the inclusion behavior of norfloxacin with 2-methyl-β-cyclodextrin, J.Incl.Phenom. Macrocycl. Chem., 62, 2008, 325-331.
99. Bilensoy E, Gürkaynak O, Ertan M, Sen M, Hincal AA, Development of nanoparticles loaded with anticancer drug paclitaxel, J. Pharm. Sci., 97, 2008, 1519-1529.
100. Guerrero-Martínez A, Montoro T, Viñas MH, Tardajos G, Complexation and Chiral Drug Recognition of an Amphiphilic Phenothiazine Derivative with β-Cyclodextrin, J. Pharm. Sci., 97, 2008, 1485-1498.
101. Araujo MVG, Macedo OFL, Nascimento CC, Conegero LS, Barreto LS, Almeida LE, Costa-Jr NB, Gimenez IF, Characterization, phase solubility and molecular modeling of α- cyclodextrin/pyrimethamine inclusion complex, Spectrochim. Acta, Part A, 72, 2009, 165-170.
102. Aski SN, Kowalewski J, Quinuclidine complex with α-cyclodextrin: A diffusion and 13C NMR relaxation study, Magn. Reson. Chem., 46, 2008, 261-267.
103. Ungaro F, Giovino C, Catanzano O, Miro A, Mele A, Quaglia F, La Rotonda MI, Use of cyclodextrins as solubilizing agentes for simvastatin: Effect of hydroxypropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium, Int. J. Pharm., 404, 2011, 49-56.